


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.62%
-1.04%
+4.25%
-0.20%
+1.92%
REGN
Regeneron Pharmaceuticals
$632.44

Login to see Regeneron Pharmaceuticals (REGN) Stock IQ rating
Get instant clarity on whether to Buy, Hold, or Avoid.
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market
Risk Analysis

Trading above its fair value
Technical Indicators

Oversold
REGN Price Performance
$766.02 (-17.44%)
$772.19 (-18.10%)
$783.71 (-19.30%)
$484.93 (+30.42%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a weak earnings
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading above its fair value
Outperform the market
REGN Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
REGN Street Sentiment is bullish and have positive views on the near-term outlook
REGN has Low risk level

Sentiments overview associated with events and the stock performance
Recent Upgrades and Downgrades
Apr 30, 2026
Reiterate
its Buy
BofA
Nov 24, 2025
Initiate
Buy
HSBC
May 18, 2026
Upgrade
Buy
H.C. Wainwright
May 18, 2026
Upgrade
Market
Leerink
Jan 09, 2026
Upgrade
Buy
Zacks
SNY
Sanofi
43.55
+0.02%
TEVA
Teva Pharma
34.11
+0.32%
KZIA
Kazia Therapeutics Limite
11.96
-4.78%
OPK
Opko Health
1.14
+0.44%
CELU
Celularity Clas
0.81
+1.30%
What is REGN current stock price?
What is REGN current Stock IQ?
What is REGN RSI signal right now?
What is REGN analyst price target and upside potential?
What do analysts say about REGN stock?
What is REGN momentum trend right now?
What are REGN stock strengths?
What is REGN Risk Level?
Should I buy REGN stock right now?
Is REGN a Strong Buy right now?
What is REGN market cap and volume?
What factors influence REGN's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
REGN
Regeneron Pharmaceuticals
Current Price
$632.44
SNY
Sanofi
43.55
+0.02%
TEVA
Teva Pharma
34.11
+0.32%
KZIA
Kazia Therapeutics Limite
11.96
-4.78%
OPK
Opko Health
1.14
+0.44%
CELU
Celularity Clas
0.81
+1.30%

REGN Price Performance
$766.02 (-17.44%)
$772.19 (-18.10%)
$783.71 (-19.30%)
$484.93 (+30.42%)
REGN Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a weak earnings
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading above its fair value
Outperform the market
REGN Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
REGN Street Sentiment is bullish and have positive views on the near-term outlook
REGN has Low risk level

Overall Wall Street Rating
REGN Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market
Risk Analysis

Trading above its fair value
Technical Indicators

Oversold
REGN Trading Signals
REGN is now at $629.68, down -9.82% from $698.25. This rapid movement warrants attention.
REGN is now at $629.68, down -9.82% from $698.25. This rapid movement warrants attention.
REGN is showing oversold conditions with RSI at 26.19 (below 30). This may signal a potential upward reversal or buying opportunity.
REGN is showing oversold conditions with RSI at 26.19 (below 30). This may signal a potential upward reversal or buying opportunity.
REGN received an analyst upgrade. Regeneron: Time To Forget Fianlimab (Rating Upgrade)....
REGN received an analyst buy rating. Here Are Mondays Top Wall Street Analyst Research Calls: Applied Materials CoreWeave Deckers Outdoor F5 Lam Research Salesforce ServiceNow Zscaler and...
REGN received an analyst buy rating. Here Are Mondays Top Wall Street Analyst Research Calls: Applied Materials CoreWeave Deckers Outdoor F5 Lam Research Salesforce ServiceNow Zscaler and...
REGN received an analyst buy rating. Here Are Mondays Top Wall Street Analyst Research Calls: Applied Materials CoreWeave Deckers Outdoor F5 Lam Research Salesforce ServiceNow Zscaler and...
REGN received an analyst price target change. Bernstein cuts Regeneron stock price target to $861 on melanoma trial failure....
REGN is experiencing a surge in social media buzz which indicates increased retail investor interest and potential momentum shift.
REGN Stock IQ dropped from 4.21 to 3.34, reflecting a weakened outlook.
REGN Stock IQ sentiment changed from Bullish to Neutral, reflecting a changed outlook.
REGN opened with a gap down of 11.79% (prev close $698.25, open $615.93)
REGN has closed down for 4 consecutive days
REGN showing early bearish trend, price below MA20 (726.12) and MA20 below MA50 (745.13)
REGN is trading 36.74% below analyst target price of $861.00, suggesting significant upside potential
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
REGN Stock trends
REGN Stock performance
REGN Stock analysis
REGN investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Read MoreNextEra Energy fell 4.63% on volume running more than 8x the daily average after confirming it will acquire Dominion Energy in an all-stock deal valued at approximately $67 billion. The combined entity would become the ...